Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Hodgkin lymphoma has long been a model disease in the field of oncology—one of the first diseases we learned to cure with radiation and ultimately…
Fred Hutch Cancer Center scientists developed an engineered antibody that may be able to target immune cells capable of producing a protective response against RSV.…
The FDA approved revumenib for the treatment of certain patients with advanced acute leukemia.The indication applies to use of the agent by adults or by…
Program for AACR Special Conference in Cancer Research: DNA Methylation, Clonal Hematopoiesis, and Cancer
Consultant Clinical Oncologist NHS advocate and campaigner Politically centre left Wealth inequality creates health inequality
In this issue of Cancer Cell, MacFawn et al. reveal that tertiary lymphoid structures (TLSs) in high-grade serous ovarian cancer (HGSOC) vary significantly by anatomical site.…
Updated interim data show high complete responses and tolerability with padeliporfin VTP in low-grade upper tract urothelial cancer.
Rachel Darwin, Senior Manager, Public Relations The National Comprehensive Cancer Network (NCCN) is honored to participate in the 4th International Congress of the Asian Oncology…
The UK MHRA approved frontline toripalimab plus chemotherapy for recurrent/metastatic NPC, as well as for advanced, recurrent, or metastatic ESCC.
